Stock BXN BIOXYNE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bioxyne Limited

Equities

BXN

AU000000BXN6

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:46 2024-04-30 am EDT 		5-day change 1st Jan Change
0.006 AUD -25.00% Intraday chart for Bioxyne Limited -33.33% -45.45%
Apr. 18 Bioxyne to Raise AU$1.45 Million via Share Issuance MT
Feb. 29 Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 32.01 11.52 6.401 17.92 7.682 38.03
Enterprise Value (EV) 1 28.7 9.755 4.701 16.32 5.514 34.75
P/E ratio -22.4 x -9 x -10.8 x -35 x -30.1 x -13.9 x
Yield - - - - - -
Capitalization / Revenue 14.9 x 5.23 x 2.76 x 8.13 x 3.09 x 7.17 x
EV / Revenue 13.3 x 4.43 x 2.02 x 7.4 x 2.22 x 6.55 x
EV / EBITDA -22.5 x -7.54 x -15.6 x -124 x -38.9 x -20.1 x
EV / FCF -18.8 x -10 x 20.4 x 34.5 x 12.4 x -63.8 x
FCF Yield -5.32% -9.95% 4.9% 2.9% 8.05% -1.57%
Price to Book 7.41 x 3.73 x 2.5 x 9.53 x 4.07 x 2.51 x
Nbr of stocks (in thousands) 640,145 640,145 640,145 640,145 640,145 1,901,645
Reference price 2 0.0500 0.0180 0.0100 0.0280 0.0120 0.0200
Announcement Date 9/27/18 9/30/19 9/30/20 9/30/21 9/30/22 9/29/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 2.151 2.202 2.322 2.204 2.485 5.305
EBITDA 1 -1.275 -1.293 -0.3009 -0.132 -0.1416 -1.726
EBIT 1 -1.288 -1.311 -0.3257 -0.1497 -0.1525 -1.836
Operating Margin -59.87% -59.54% -14.03% -6.79% -6.14% -34.6%
Earnings before Tax (EBT) 1 -1.312 -1.266 -0.5931 -0.4957 -0.2365 -1.964
Net income 1 -1.312 -1.266 -0.5931 -0.4957 -0.2365 -1.94
Net margin -60.98% -57.48% -25.55% -22.49% -9.52% -36.57%
EPS 2 -0.002231 -0.002000 -0.000926 -0.000799 -0.000399 -0.001443
Free Cash Flow 1 -1.526 -0.9711 0.2305 0.4728 0.4436 -0.5448
FCF margin -70.92% -44.09% 9.93% 21.45% 17.85% -10.27%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/27/18 9/30/19 9/30/20 9/30/21 9/30/22 9/29/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 3.31 1.77 1.7 1.6 2.17 3.29
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.53 -0.97 0.23 0.47 0.44 -0.54
ROE (net income / shareholders' equity) -31% -33.9% -20.6% -21.8% -12.2% -26.8%
ROA (Net income/ Total Assets) -16.4% -18.2% -5.57% -3.11% -3.4% -12.7%
Assets 1 7.977 6.968 10.64 15.93 6.951 15.34
Book Value Per Share 2 0.0100 0 0 0 0 0.0100
Cash Flow per Share 2 0.0100 0 0 0 0 0
Capex 1 0.17 0.06 0.03 - 0.01 0.06
Capex / Sales 7.97% 2.89% 1.45% - 0.23% 1.07%
Announcement Date 9/27/18 9/30/19 9/30/20 9/30/21 9/30/22 9/29/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIOXYNE LIMITED Stock Bioxyne Limited
-45.45% 10.74M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.86B
MODERNA, INC. Stock Moderna, Inc.
+10.92% 42.74B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 41.36B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 27.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 25.15B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.63B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 11.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BXN Stock
  4. Financials Bioxyne Limited